Company History

You are here: Home » About Us » Company History

Endosense was founded in 2003 in Geneva by accomplished interventional cardiologist Dr. Vitali Verin and seasoned engineers Giovanni Leo and Nicolas Aeby to deliver breakthrough advances to the catheter ablation treatment of cardiac arrhythmias. Their primary focus was to develop an effective means of real-time contact force assessment between the catheter tip and the beating heart wall, a significant clinical problem with no viable solution.

Backed by $20 million in Series A financing, Endosense embarked in 2005 on extensive pre-clinical study of the TactiCath®, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Between 2006 and 2008, the results of 10 pre-clinical studies of the TactiCath were presented at major clinical meetings around the world; and, in 2008, the company launched TOCCATA, a 76-patient, multi-center European study designed to evaluate the safety and value of force-sensing in the catheter ablation procedure.

Based on the success of the TOCCATA study, Endosense was granted the CE mark for the TactiCath in 2009 for its first generation product. The company also received $36 million in Series B financing and signed BIOTRONIK as its exclusive TactiCath distributor in Europe, Latin America, Africa and the Middle East in the same year. Endosense launched its second generation product in April 2010, followed by the launch of the EFFICAS study series in May 2010. Endosense launched an  Investigational Device Exemption (IDE) study in the United States beginning of 2011.

In June 2012, the company launched its new product line, comprised of the TactiCath Quartz and the TactiSys Quartz, which offer several key innovations over the previous model. The catheter features a new force sensor that provides increased stability and precision and avoids the need for pre-procedure calibration; a significantly smaller equipment footprint; a user friendly graphical interface; and, enhanced signal processing and digital output that facilitates connectivity with imaging devices and other equipment in the lab.

The same year, Endosense received $36.9 million in Series C financing and built a new sales & marketing organization to accelerate adoption of this innovative technology in order for contact force to become a standard of care.